Aurobindo Pharma Ltd. - Research Center
524804 AUROPHARMA Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 24 | Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | |
|---|---|---|---|---|---|
| Sales | 5,284.68 | 5,059.58 | 5,812.58 | 5,510.22 | 5,776.93 |
| Operating profit | 1,219.81 | 967.56 | 538.16 | 722.88 | 750.54 |
| Interest | 102.76 | 68.28 | 27.05 | 8.45 | 8.50 |
| Gross profit | 1,305.03 | 1,061.24 | 605.68 | 1,259.09 | 868.36 |
| EPS (Rs) | 14.92 | 12.83 | 4.89 | 17.78 | 7.04 |
Half yearly
results in details
| Sep ' 24 | Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | |
|---|---|---|---|---|---|
| Other income | 187.98 | 161.96 | 94.57 | 544.66 | 126.32 |
| Stock adjustment | -66.81 | -43.37 | -81.17 | 28.86 | 16.65 |
| Raw material | 2,742.92 | 2,893.59 | 3,201.56 | 2,838.27 | 2,945.66 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 524.81 | 483.57 | 816.81 | 779.99 | 820.05 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 863.95 | 758.23 | 1,337.22 | 1,140.22 | 1,244.03 |
| Provisions made | - | - | - | - | - |
| Depreciation | 135.04 | 125.42 | 211.85 | 202.42 | 212.83 |
| Taxation | 303.42 | 238.17 | 107.04 | -60.01 | 242.78 |
| Net profit / loss | 866.57 | 751.69 | 286.79 | 1,041.97 | 412.75 |
| Extra ordinary item | - | 54.04 | - | -74.71 | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 58.08 | 58.59 | 58.59 | 58.59 | 58.59 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 23.08 | 19.12 | 9.26 | 13.12 | 12.99 |
| GPM (%) | 23.85 | 20.32 | 10.25 | 20.79 | 14.71 |
| NPM (%) | 15.83 | 14.40 | 4.85 | 17.21 | 6.99 |
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis